Pilot trial finds tocilizumab may improve inflammatory depression

A small clinical trial has provided early evidence that an existing anti-inflammatory drug may offer a new treatment path for patients with difficult-to-treat depression. The study, led by researchers at the University of Bristol and published in JAMA Psychiatry, investigated the effects of tocilizumab, a medication commonly used for rheumatoid arthritis, on individuals with moderate to severe depression who had not responded to standard antidepressants.

The four-week pilot trial involved 30 participants who showed signs of low-grade inflammation in repeated blood tests. Participants were randomly assigned to receive either weekly injections of tocilizumab or a placebo. While the small size of the study meant the results did not reach statistical significance, researchers observed a pattern of greater improvement over time in the group receiving the drug. These improvements included reductions in overall depression severity, fatigue, and anxiety, as well as increased quality of life.

Notably, 54 percent of patients in the tocilizumab group achieved clinical remission from depression, compared to 31 percent in the placebo group. This outcome equates to a Number Needed to Treat...